Paul Trey Knollman

NanoCellect is committed to empowering every scientist to make discoveries one cell at a time, with modern and simple technologies for to advance cell based assays that are affordable, compact, and easy-to-use. Our microfluidic flow cytometry platforms enable biomedical scientists to analyze and sort cells required for drug discovery, single cell-omics, cloning, and basic research. The company was founded in late 2009 as a spinout from UCSD and dedicated 6 years developing the foundation of the WOLF’s technology before introducing the WOLF to early adopters in 2016. Initial funding of R&D was graciously provided by multiple NIH SBIR grants and contracts. Additionally, we are backed by Illumina Ventures, FusionX Ventures, Anzu Partners, Agilent Technologies, Vertical Ventures and other private investors.

Sales, Marketing, and Application Support team structure, processes, tooling/tech stacks, funnel, and sales analysis for biotechnology product lines and services. Provide in-depth current state and recommendations to support high revenue growth (>25% YOY), with expertise in research, drug discovery, and translational science segments.

Training, coaching, and managing a team of 3 Sales Directorsand 1 Customer Success Representative and reporting to the CEO. Active within the Executive leadership team with strategic planning, product development guidance, quarterly board meetings, and executing to the worldwide sales plan. In late 2019, Amplion launched a best-in-class, machine-learning software platform designed for commercial teams in the life science, clinical development, and pharma services space which automatically identifies new sales opportunities by adapting NLP algorithms to our customers’ product/services technical capabilities. Amplion also offers Data Services, that cater to therapeutic portfolio managers and are a project based spreadsheet deliverable. Launched first software product, Amplion Intelligence, that delivered thefirst $500k of ARR at a $25k ARR/user price point for the company. Amplion ($8M Series A Corporation as of 2021) works with Diagnostic Test Developers (RUO-CDx), Life Science Tool, and Research/Clinical CROs to help their commercial teams identify new business and partnership opportunities with Pharma, Biotechs and Academia. We have helped our customers achieve a 2x increase in qualified opportunities and 33% increase in opportunity win rate as a result of integrating Amplion Intelligence Platform software into their sales, business development, and marketing processes. The Amplion Intelligence Platform synthesizes the world’s vast biomedical knowledge base using a machine-learning approach and web-based user interface. 32M+ pieces of scientific evidence across 20,000 Biotechnology and Research organizations, 85k active clinical trials, and 30k new publications every week are mined to identify and alert Amplion users of new organizations and opportunities that precisely meet your Product/Services capabilities.

Player/Coach role and reported to VP Sales then CEO. Managed new team of 4 covering NW, SW, Central, and SE Territories. Focused efforts on market development, sales funnel management, opportunity add, sales process development for single cell proteomic analysis instrumentation in the translational research/clinical biomarker markets. IsoPlexis ($250M Series D Corporation as of 2021) is transforming precision oncology in cell and cancer immunotherapy by defining the complete function of each cell for the first time. The Isolight profiles immune responses at the single cell level, to generate direct, precise functional signatures. Our readouts predict and explain complex patient response to cell and other cancer immunotherapies. IsoPlexis’ real-world clinical data with leading biopharmaceuticals and trial centers is accelerating data driven immuno-oncology.

Reported to VP NA Sales. Managed 9 Territory Reps and 1 Sales Manager supporting HT flow cytometry and live-cell imaging portfolios (instruments, consumables, service contracts, and associated assay kits). Top performing Region (% to Quota) in North America Q2 and Q3 2018. The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than 1.3 billion euros in 2016. Around 7,000 people work for the Group, which has its own manufacturing and sales sites in around 110 countries.

Individual contributor, reported to VP NA Sales. Responsible for identifying and closing new business for flow cytometry instrumentation (~$200-300k), assay kits, and service contracts. Exceeded >$2M quota while building new and maintaining current relationships with customers. Awarded 2016 Worldwide Rookie of the Year for Instrumentation and 2016 Worldwide Rookie of the Year for Consumable sales (147% to Quota). Awarded 2017 Worldwide Top Sales (110% to Quota). IntelliCyt Corporation ($90 Sartorius 2016 aquisiton) develops innovative, high-throughput, high-content cell and bead-based screening solutions for use in phenotypic drug discovery, antibody discovery and in vitro toxicity testing. IntelliCyt's proprietary technologies, instrumentation, assays and software products address the pervasive need to provide turnkey solutions that increase productivity in pharmaceutical, biotechnology, and life science research. Founded in 2006 by life science entrepreneurs and leading scientists, IntelliCyt Corporation was the first to commercialize a true high throughput screening platform for suspension cells that addresses urgent unmet research needs. Our flagship product, the iQue® Screener combines the sensitive, proven detection technology of flow cytometry with a patented sample processing technology, running a 96-well microplate in 3 minutes. The iQue Screener is part of a complete solution of application-specific reagent kits and software that addresses the growing need for high throughput, high content cell based assays.

Individual contributor, reported to the Global Sales Director. Responsible for identifying and driving new business in academic, biotech, and pharmaceutical accounts. Exceeded annual territory sales quotas of $1M+ for capital expense live-cell imaging systems (~$150k) and associated assay kits. Worked with Scientist to VP level clients in a variety of research fields including: cell and developmental biology, regenerative medicine, oncology, immunology, immuno-oncology, virology, metabolism, and cardiovascular biology. Developed rich customer relationships through scientific presentations, instrument demonstrations, unmatched technical support, and consistent presence. Supported numerous internal R&D, VOC, and Marketing efforts while growing territory >30% YOY from 2012-2015 (100+% to Quota). Essen Bioscience ($320M Sartorius 2017 Aquisition) is a leading instrument and service provider in the life science research field with a long history of product innovation. Products invented by Essen Personnel include the first high throughput cell-based assay platform FLIPR; the first high throughput planar electrophysiology platform on the market, IonWorks and the first live cell imaging system to fit inside a standard cell culture incubator, Incucyte. Recently, Essen has expanded their instrumentation-based business models to also include contract services, assembling a team of senior scientists who have successfully managed and driven drug discovery projects at major pharmaceutical companies. The combination of drug discovery and instrumentation experience makes Essen a unique provider of life science research tools and services.

Reported to the Associate Director. I was a key member of a research and development team responsible for conception, development, and commercialization of primary and stem cell culture systems and assays for academic research and pharmaceutical development applications. I launched 6 new products which contributed to over $500K in new revenues over 3 years post-launch while supporting various other products with application data and marketing collateral. I was trained in understanding the Voice of Customer (VOC), User Centered Innovation (UCI), and Design for Six Sigma practices, and implemented those tools in my product development efforts programs across multiple business units. I was an active member in marketing and product awareness campaigns, through a variety of efforts including: website and social media channel content creation and analytics, customer segmentation and marketing campaign design and execution, customer and scientific conference presentations, and through training sales and customer support functions. I presented numerous posters at conferences and co-authored 1 peer reviewed article in a high-impact journal. About Life Technologies: Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to improving the human condition. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and TaqMan® products. Life Technologies had sales of $3.7 billion in 2011, employs approximately 10,400 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 4,000 patents and exclusive licenses.

Reported to 2 Primary Investigators. Responsible for molecular biology efforts in a research group interrogating the structure and function of the CFTR chloride channel. Generated a library of CFTR genetic mutants for subsequent oocyte injection and electrophysiology assays (single cell patch clamp and two-electrode voltage clamp) to identify pore-lining residues in the channel for novel drug discovery and potential therapeutic interventions. Routinely performed cell-based and biochemical assays interrogating G-protein coupled receptor function and signaling. I authored 2 and co-authored 4 additional peer reviewed articles in high-impact journals. About OHSU: The Physiology and Pharmacology Department offers a unique environment for research and training that combines elements of Molecular Physiology and Pharmacology with Chemical Biology to create a synergistic and highly collaborative atmosphere. Oregon Health & Science University is the state’s only academic health center. It provides an uncommon array of services from providing the state’s most comprehensive health care, to educating the next generation of clinicians and biomedical researchers, to achieving breakthroughs and innovations. Its hospitals and clinics serve more than a quarter of a million patients every year with innovative care and treatment models based on the latest knowledge available. From humble beginnings in 1887, OHSU has grown into a world-class teaching hospital and research center that draws in students, scientists and patients from across the country and around the globe.